Zurueck zur Suche

Reporte zur Charge 25N39

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

10Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
WI 1 WA 1 TX 1 CA 1 AL 1 IL 1 NE 1 CO 1 MI 1

VAERS 2669301

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge 25N39

moderat
Staat
WI
Alter
19,0
Geschlecht
F
Eingang
10.08.2023
Impfdatum
09.08.2023
Beginn
09.08.2023
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: nein
Chest pain Dizziness Pharyngeal swelling Rash Swelling Throat irritation

Symptomtext

Approximately 20 minutes after receiving the injection patient noted chest pain, itchy throat, throat swelling, rash on left arm, rash/swelling left neck, dizziness. Patient was taken to ER for evaluation.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Chest pain
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
None
Allergien
Tdap vaccine- itchy throat, chest pain, rash on skin, some throat swelling
Vorherige Impfungen
Tdap (Boostrix)- chest pain, rash, itchy throat.

VAERS 2706998

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge 25N39

gering
Staat
-
Alter
60,0
Geschlecht
M
Eingang
31.10.2023
Impfdatum
18.10.2023
Beginn
18.10.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Underdose

Symptomtext

report the administration of a pediatric Engerix-B dose to a 60-year-old patient; report the administration of a pediatric Engerix-B dose to a 60-year-old patient; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a 60-year-old male patient who received HBV (Engerix B pediatric) (batch number 25N39, expiry date 16-MAR-2024) for prophylaxis. On 18-OCT-2023, the patient received Engerix B pediatric. On 18-OCT-2023, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: report the administration of a pediatric Engerix-B dose to a 60-year-old patient) and underdose (Verbatim: report the administration of a pediatric Engerix-B dose to a 60-year-old patient). The outcome of the adult use of a child product and underdose were unknown. Additional Information: GSK receipt date 20 Oct 2023 A pharmacist called to report the administration of a pediatric Engerix-B dose to a 60-year-old patient. The HCP asked for guidance on this situation, which led to adult use of a child product and underdose . The reporter did not consent to follow-up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Underdose
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2647538

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge 25N39

gering
Staat
WA
Alter
49,0
Geschlecht
M
Eingang
21.06.2023
Impfdatum
09.06.2023
Beginn
09.06.2023
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product administered to patient of inappropriate age Underdose

Symptomtext

Engerix-B second dose pediatric formulation instead of the adult; Engerix-B second dose pediatric formulation instead of the adult; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of underdose in a 50-year-old male patient who received HBV (Engerix B 10 mcg) (batch number 25N39, expiry date 16-MAR-2024) for prophylaxis. Previously administered products included Engerix-B (1st dose received on an unknown date). On 09-JUN-2023, the patient received the 2nd dose of Engerix B 10 mcg. On 09-JUN-2023, an unknown time after receiving Engerix B 10 mcg, the patient experienced underdose (Verbatim: Engerix-B second dose pediatric formulation instead of the adult) and adult use of a child product (Verbatim: Engerix-B second dose pediatric formulation instead of the adult). The outcome of the underdose and adult use of a child product were unknown. Additional Information: GSK receipt date: 15-JUN-2023 The Engerix-B first dose was administered on another pharmacy and that is why there were no details available about that dose. Follow-up declined. The reporter did not consent to follow-up. An adult patient received Engerix-B dose pediatric formulation instead of the adult, which led to underdose and adult use of a child product.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product administered to patient of inappropriate age
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2623450

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge 25N39

gering
Staat
TX
Alter
24,0
Geschlecht
F
Eingang
28.04.2023
Impfdatum
19.04.2023
Beginn
19.04.2023
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product administered to patient of inappropriate age Underdose

Symptomtext

Adult received Pediatric dose; Adult received Pediatric dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of underdose in a 24-year-old female patient who received HBV (Engerix B pediatric) (batch number 25N39, expiry date 16-MAR-2024) for prophylaxis. On 19-APR-2023, the patient received Engerix B pediatric. On 19-APR-2023, an unknown time after receiving Engerix B pediatric, the patient experienced underdose (Verbatim: Adult received Pediatric dose) and adult use of a child product (Verbatim: Adult received Pediatric dose). The outcome of the underdose and adult use of a child product were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 20-Apr-2023 The pharmacist asked that how to proceed. The vaccine administration facility was the same as primary reporter. The reporter consented to follow-up. An adult patient received an pediatric dose of Engerix-B, which led to underdose and adult use of a child product.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product administered to patient of inappropriate age
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2567158

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge 25N39

gering
Staat
CA
Alter
33,0
Geschlecht
M
Eingang
25.01.2023
Impfdatum
19.07.2022
Beginn
19.07.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product administered to patient of inappropriate age Underdose

Symptomtext

pediatric dose given to adult patient; pediatric dose given to adult patient; This case was reported by a pharmacist via call center representative and described the occurrence of underdose in a 33-year-old male patient who received HBV (Engerix B 10 mcg) (batch number 25N39, expiry date 16th March 2024) for prophylaxis. On 19th July 2022, the patient received Engerix B 10 mcg 10 ug. On 19th July 2022, unknown after receiving Engerix B 10 mcg, the patient experienced underdose and adult use of a child product. On an unknown date, the outcome of the underdose and adult use of a child product were unknown. Additional Information: GSK Receipt Date: 17-JAN-2023 Reporter's Comments: The pharmacist reported pediatric dose given to adult patient. Adverse event contained all reported information. The reporter consented to follow up. Additional Supportive Information: The adult patient received Engerix B pediatric dose, which led to underdose and adult use of a child product.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product administered to patient of inappropriate age
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2538584

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge 25n39

gering
Staat
AL
Alter
33,0
Geschlecht
M
Eingang
21.12.2022
Impfdatum
07.12.2022
Beginn
07.12.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product administered to patient of inappropriate age Underdose

Symptomtext

Pediatric dose administered to adult; Pediatric dose administered to adult; This case was reported by a pharmacist via call center representative and described the occurrence of underdose in a 33-year-old male patient who received HBV (Engerix B pediatric) (batch number 25n39, expiry date 16th March 2024) for prophylaxis. Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis. On 7th December 2022, the patient received Engerix B pediatric and Engerix B Pre-Filled Syringe Device. On 7th December 2022, unknown after receiving Engerix B pediatric and Engerix B Pre-Filled Syringe Device, the patient experienced underdose and adult use of a child product. On an unknown date, the outcome of the underdose and adult use of a child product were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 9-Dec-2022 Reporter's comment: The reporter did not consent to follow-up. Additional supportive information: The patient inadvertently administered pediatric dose of Engerix-B instead of an adult dose, which led to underdose and adult use of a child product.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product administered to patient of inappropriate age
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2517558

GLAXOSMITHKLINE BIOLOGICALS · HIB (HIBERIX) · Charge 25N39

gering
Staat
IL
Alter
-
Geschlecht
U
Eingang
28.11.2022
Impfdatum
18.01.2022
Beginn
18.01.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product administered to patient of inappropriate age Skin discolouration

Symptomtext

Gray dot on thigh; 1st dose: 18-JAN-2022; This case was reported by a nurse and described the occurrence of skin discoloration in a patient who received Hib (Hiberix) (batch number 25N39, expiry date unknown) for prophylaxis. On 18th January 2022, the patient received the 1st dose of Hiberix. On 18th January 2022, unknown after receiving Hiberix, the patient experienced inappropriate age at vaccine administration. On an unknown date, the patient experienced skin discoloration. On an unknown date, the outcome of the skin discoloration and inappropriate age at vaccine administration were unknown. It was unknown if the reporter considered the skin discoloration to be related to Hiberix. Linked case(s) involving the same patient: US2022AMR171197, US2022AMR171230 Additional Information: GSK Receipt Date: 16-NOV-2022 Reporter's Comment: he reporter reported that the patient after received Hiberix and experienced gray dot on the legs. The patient received Hiberix vaccine on the day of birth. Additional supportive information: The patient received Hiberix who was younger than the indicated age which led to inappropriate age at vaccine administration. This case had been linked with US2022AMR171197 and US2022AMR171230 by same reporter for same patient.; Sender's Comments: US-GSK-US2022AMR171025:Same reporter US-GSK-US2022AMR171007:Same reporter US-GSK-US2022AMR171034:Same reporter US-GSK-US2022AMR171044:Same reporter US-GSK-US2022AMR171042:Same reporter US-GSK-US2022AMR171039:Same reporter US-GSK-US2022AMR171028:Same reporter US-GSK-US2022AMR149561:Same reporter US-GSK-US2022AMR149560:Same reporter US-GSK-US2022AMR149551:Same reporter US-GSK-US2022AMR148962:Same reporter US-GSK-US2022AMR148961:Same reporter US-GSK-US2022AMR148919:Same reporter US-GSK-US2022AMR171056:Same reporter US-GSK-US2022AMR171052:Same reporter US-GSK-US2022AMR171062:Same reporter US-GSK-US2022AMR171050:Same reporter US-GSK-US2022AMR171048:Same reporter US-GSK-US2022AMR171083:Same reporter US-GSK-US2022AMR171088:Same reporter US-GSK-US2022AMR171095:Same reporter US-GSK-US2022AMR171047:Same reporter US-GSK-US2022AMR171154:Same reporter US-GSK-US2022AMR171088:Same reporter US-GSK-US2022AMR171095:Same reporter US-GSK-US2022AMR171083:Same reporter US-GSK-US2022AMR171154:Same reporter US-GSK-US2022AMR171174:Same reporter US-GSK-US2022AMR171169:Same reporter US-GSK-US2022AMR171197:Same reporter US-GSK-US2022AMR171230:Same reporter US-GSK-US2022AMR171088:Same reporter US-GSK-US2022AMR171154:Same reporter US-GSK-US2022AMR171095:Same reporter US-GSK-US2022AMR171047:Same reporter US-GSK-US2022AMR171174:Same reporter US-GSK-US2022AMR171169:Same reporter US-GSK-US2022AMR171083:Same reporter US-GSK-US2022AMR171197:Same reporter US-GSK-US2022AMR148961: US-GSK-US2022AMR149561: US-GSK-US2022AMR149560:

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product administered to patient of inappropriate age
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2401068

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge 25N39

gering
Staat
NE
Alter
20,0
Geschlecht
F
Eingang
04.08.2022
Impfdatum
15.07.2022
Beginn
15.07.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product administered to patient of inappropriate age Underdose

Symptomtext

pediatric dose instead of adult one; pediatric dose instead of adult one; This case was reported by a other health professional via call center representative and described the occurrence of underdose in a 20-year-old female patient who received HBV (Engerix B pediatric) (batch number 25N39, expiry date 16th March 2024) for prophylaxis. On 15th July 2022, the patient received Engerix B pediatric. On 15th July 2022, unknown after receiving Engerix B pediatric, the patient experienced underdose and adult use of a child product. On an unknown date, the outcome of the underdose and adult use of a child product were unknown. Additional Information: GSK receipt date: 01-Aug-2022 Reporter's comment: The reporter reported that the patient received a pediatric dose of Engerix instead of an adult one. The reporter consented to follow-up. Additional supportive information: The patient received a pediatric dose of Engerix instead of an adult one, which led to underdose and adult use of a child product.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product administered to patient of inappropriate age
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2173159

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge 25N39

gering
Staat
CO
Alter
87,0
Geschlecht
F
Eingang
11.03.2022
Impfdatum
07.02.2022
Beginn
07.02.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Accidental underdose Product administered to patient of inappropriate age

Symptomtext

adult administered a pediatric dose; adult administered a pediatric dose; This case was reported by a other health professional via call center representative and described the occurrence of accidental underdose in a 87-year-old female patient who received HBV (Engerix B 10 mcg) (batch number 25N39, expiry date 16th March 2024) for prophylaxis. Previously administered products included Engerix B with an associated reaction of therapy non-responder (previously completed the series on an unknown date, but titer testing was negative, refer link case US2022AMR044159) and Engerix B (1st dose received on an unknown date of readministered series). On 7th February 2022, the patient received the 2nd dose of Engerix B 10 mcg. On 7th February 2022, unknown after receiving Engerix B 10 mcg, the patient experienced accidental underdose and adult use of a child product. On an unknown date, the outcome of the accidental underdose and adult use of a child product were unknown. Additional details were reported as follows: The medical assistant reported that, an adult patient was inadvertently administered a pediatric dose of Engerix-B, which led to accidental underdose and adult use of a child product. At the time of reporting, this dose had not been repeated. This patient previously completed the series, but titer testing was negative, so the series was being re-administered, refer linked case US2022AMR044159. The reporter consented to follow up. This case had been linked with case US2022018153, reported by the same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2022018153:Same reporter US-GLAXOSMITHKLINE-US2022AMR044159:same reporter

Weitere VAERSDATA-Felder
Praegender Schweregrund
Accidental underdose
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1957726

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge 25N39

gering
Staat
MI
Alter
24,0
Geschlecht
M
Eingang
17.12.2021
Impfdatum
10.12.2021
Beginn
10.12.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Accidental underdose Adult failure to thrive

Symptomtext

was administered a pediatric dose of Engerix-B inadvertently; was administered a pediatric dose of Engerix-B inadvertently; This case was reported by a other health professional via call center representative and described the occurrence of accidental underdose in a 24-year-old male patient who received HBV (Engerix B pediatric) (batch number 25N39, expiry date 16th March 2024) for prophylaxis. On 10th December 2021, the patient received the 2nd dose of Engerix B pediatric. On 10th December 2021, unknown after receiving Engerix B pediatric, the patient experienced accidental underdose and adult use of a child product. On an unknown date, the outcome of the accidental underdose and adult use of a child product were unknown. Additional details were provided as follows: The medical assistant reported that, the patient inadvertently administered a pediatric dose of Engerix B, which led to accidental underdose and adult use of a child product. The reporter consented to follow up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Accidental underdose
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-